T. Rowe Price Investment Management
THRD

T. Rowe Price Investment Management’s Third Harmonic Bio THRD Stock Holding History

T. Rowe Price Investment Management’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,929,498
Closed -$30.1M – 696
2024
Q4 		$30.1M Buy
2,929,498
+99,250
+4% +$1.24M 0.02% 474
2024
Q3 		$38.4M Buy
2,830,248
+1,481,014
+110% +$18.3M 0.02% 446
2024
Q2 		$17.5M Buy
+1,349,234
New +$16.7M 0.01% 511

Other funds holding THRD

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

T. Rowe Price Investment Management's THRD Position: Q1 2025 in Review

T. Rowe Price Investment Management sold out of Third Harmonic Bio (THRD) in Q1 2025, closing a stake of 2,929,498 shares — an estimated $30.1M sold.

T. Rowe Price Investment Management first reported a position in THRD in Q2 2024 and held it in 3 quarters. The position peaked at $38.4M in Q3 2024. 100 funds tracked by Wall St. Rank hold THRD as of Q1 2025.

  • T. Rowe Price Investment Management reported no remaining Third Harmonic Bio position as of Q1 2025 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 2,929,498 Third Harmonic Bio shares in Q1 2025, an estimated $30.1M.
  • T. Rowe Price Investment Management first reported a position in Third Harmonic Bio in Q2 2024 and held it in 3 quarters.
  • T. Rowe Price Investment Management's Third Harmonic Bio position peaked at $38.4M in Q3 2024.
  • 100 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q1 2025.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2025, filed 14 May 2025.